Following the loss of the hypertension drug Diovan (valsartan) in September, Novartis AG has a little – but just a little – breathing room before its next big cliff: the loss of exclusivity for its leukemia drug Gleevec (imatinib), likely beginning in the U.S. in July 2015. The impending loss of the mega blockbuster that catapulted Novartis into a leading oncology player is putting pressure on the Swiss pharma to bring new cancer drugs to market to maintain growth within oncology, its largest franchise.
The company is banking on launching six oncology drugs before 2016, products now in development that management highlighted during an R&D Day for investors held on Nov
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?